CAPR

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Maurer Michael TCHIEF COMMERCIAL OFFICER --80k shares Grant / ExerciseMay 26, 2026 $2.3M80k shares $29.36 $29.14

News

globenewswire.comCapricor Therapeutics to Present at Upcoming Investor Conferencesglobenewswire.comJun 8

seekingalpha.comCapricor: I Rate It A Buy After Stress-Testing The Sell Thesisseekingalpha.comJun 3

seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 12

marketbeat.comCapricor Therapeutics Q1 Earnings Call Highlightsmarketbeat.comMay 12

globenewswire.comCapricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 12

Trade CAPR

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medical conditions. Furthermore, Capricor is developing two vaccine candidates with the potential to prevent COVID-19. Capricor collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, supporting its use in DMD and other indications. The company was established in 2005 and is headquartered in San Diego, California.

CEO: Linda Marbán
IPO Date: Feb 13, 2007

Market Data

Open: $26.52
High: $26.97
Low: $25.07
Volume: 962.9K
52W High: $40.37
52W Low: $4.30

Valuation

Market Cap: $1.2B
Enterprise Value: $1.1B

Financials

Free Cash Flow: $-73M
Revenue: $0
Net Income: $-105M
Cash: $288M
Debt: $21M

Events

EarningsAug 11

EPS est. -0.58